Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head

Acta Orthopaedica

Volumn 80, Issue 3, 2009, Pages 325-329

  He, Wei ^a   Li, Keda ^a  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABCB1 PROTEIN, HUMAN; CORTICOSTEROID; CYTOCHROME P450 3A; GLYCOPROTEIN P;

ADOLESCENT; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMUR HEAD NECROSIS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; LIPID METABOLISM; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; CHILD; COHORT STUDIES; CYTOCHROME P-450 CYP3A; FEMUR HEAD NECROSIS; GENOTYPE; HUMANS; LIPID METABOLISM; MIDDLE AGED; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 74249083535     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453670903025378     Document Type: Article

References (29)

1. Asano T, Takahashi K A, Fujioka M, Inoue S, Okamoto M, Sugioka N, et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003a; 13: 675-82. (Pubitemid 38316511)
2. Asano T, Takahashi K A, Fujioka M, Inoue S, Satomi Y, Nishino H, et al. Genetic analysis of steroid-induced osteonecrosis of the femoral head. J Orthop Sci 2003b; 8: 329-33. (Pubitemid 36702081)
3. Drescher W, Li H, Lundgaard A, Bunger C, Hansen E S, Endothelin-1-induced femoral head epiphyseal artery constriction is enhanced by long-term corticosteroid treatment. J Bone Joint Surg (Am) (Suppl 3) 2006; 88: 173-9. (Pubitemid 44706500)
4. Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y, et al. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 2006; 7: 831-41. (Pubitemid 44446734)
5. Felix C A, Walker A H, Lange B J, Williams T M, Winick N J, Cheung N K, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998; 95: 13176-81. (Pubitemid 28509544)
6. Hoffmeyer S, Burk O, von Richter O, Arnold H P, Brockmoller J, Johne A, et al., Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-8. (Pubitemid 30183327)
7. Hsieh K P, Lin Y Y, Cheng C L, Lai M L, Lin M S, Siest J P, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29: 268-73.
8. Kim R B, Leake B F, Choo E F, Dresser G K, Kubba S V, Schwarz U I, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-99. (Pubitemid 32777772)
9. Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kanakubo Y Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations. Biochem Pharmacol 1987; 36: 453-6. (Pubitemid 17024166)
10. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30: 1108-14.
11. Li Y, Wang Y, Sun J, Li Y, Yang L. Distribution of the functional MDR1 C3435T polymorphism in the Han population of China. Swiss Med Wkly 2006; 136: 377-82. (Pubitemid 43962689)
12. Lieberman J R, Berry D J, Mont M A, Aaron R K, Callaghan J J, Rajadhyaksha A D, et al. Osteonecrosis of the hip: management in the 21st century. Instr Course Lect 2003; 52: 337-55.
13. Mankin H J. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326: 1473-9.
14. Masada T, Iwakiri K, Oda Y, Kaneshiro Y, Iwaki H, Ohashi H, et al. Increased hepatic cytochrome P4503A activity decreases the risk of developing steroid-induced osteonecrosis in a rabbit model. J Orthop Res 2008; 26: 91-5.
15. Naud J, Mchaud J, Leblond F A, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos 2008; 36: 124-8.
16. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-80. (Pubitemid 23099291)
17. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400-4. (Pubitemid 32977244)
18. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002; 25: 1391-400. (Pubitemid 39663152)
19. Schroer W C. Current concepts on the pathogenesis of osteonecrosis of the femoral head. Orthop Rev 1994; 23: 487-97. (Pubitemid 24206357)
20. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572-83. (Pubitemid 36237729)
21. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847-54. (Pubitemid 34700609)
22. Sugano N, Atsumi T, Ohzono K, Kubo T, Hotokebuchi T, Takaoka K. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci 2002; 7: 601-5. (Pubitemid 35238873)
23. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-43. (Pubitemid 32472514)
24. Thervet E, Anglicheau D, King B, Schlageter M H, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233-5. (Pubitemid 37339651)
25. Tsuji A, Sakata I, Tamai I. Tissue distribution of the mdr gene product PGP and its physiological function. Nippon Rinsho 1997; 55: 1059-63.
26. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1676-83. (Pubitemid 40852875)
27. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong V W. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-52. (Pubitemid 32493590)
28. Wen S, Wang H, Ding Y, Liang H, Wang S. Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray. Genet Test 2004; 8: 411-6. (Pubitemid 40083107)
29. Yates C R, Zhang W, Song P, Li S, Gaber A O, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555-64. (Pubitemid 36613114)